AKT1 and neoplasm: Immunotherapy advances include engineered bone marrow-derived mesenchymal stem cells (BMSCs) delivering sPD1 and IFNγ, which enhance T cell activation, suppress PI3K/AKT/PD-L1 pathways, and promote tumor cell senescence [269].